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Will Social Values Influence the Development
of HMOs?
JOHN B. DAVIS

Among industrialized nations the
United States is relatively unique in
relying on a mix of public and private
financing and delivery of healthcare:
federal and federal-state programs,
such as Medicare and Medicaid;
employment-based health insurance
(primarily HMOs); and state-subsidized
insurance pools for high-risk individuals. In recent years, however, there
have been efforts to apply the principles of private employment-based
health insurance to the other forms of
healthcare, and there is speculation that
rising healthcare costs can only be
addressed by further extending capitated payment plans. This suggests that
U.S. healthcare may increasingly be
organized according to market principles. For some, this represents a historic departure from an emphasis on
public responsibility for healthcare and
a sacrifice of the value principles
embodied in health relationships
between patient and provider. But
defenders of HMOs and a larger role
for markets argue that managed care
allows for a more rational allocation
of scarce healthcare resources by minimizing inefficient low-benefit-highcost care. More individuals receive
essential care if inessential care is eliminated. HMOs are also said to encourage non-HMOs to provide lower priced
healthcare.
Interestingly, recent evidence suggests that HMO market share will not
continue to expand through price and
cost competition but only if HMOs
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address quality of care-in market
terms, a process understood by economists as product differentiation. But
there is a complication. Unlike other
types of consumption, healthcare is
consumed in "bundles" whose composition depends on a shared decisionmaking process between patients and
healthcare providers. This decisionrnaking exhibits nonrnarket values that may
constitute a barrier to the extension of
market principles through product differentiation. Here, I look at these economic and social value issues to
consider how healthcare delivery may
evolve in the United States in the
future .
HMO Expansion: Experience and
Prospects
HMOs have increased market share
by cost-containment strategies involving physician oversight and incentive
adjustment, fewer and shorter hospitalization stays, and fewer and less
diagnostic testing.1 Their success at
cost containment is due in large part
to selection bias in enrolling healthierthan-average patients previously
enrolled in traditional plans. To compete, non-HMOs have also had to
charge lower premiums, despite being
left with less healthier-than-average,
more costly patients. Together this
should imply lower average premiums across HMO and non-HMOs.
There is evidence, however, that where
HMOs have achieved large market
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share average premiums are higher.2
Why?
Baker and Corts ask whether nonHMO premiums fall when HMO market share is low due to competitive
pressures, and then rise when HMO
market share rises due to changing
patient pools.3 They find that nonHMO premiums fall until HMO market share is about 15 percent, and rise
thereafter. But as HMO shares rise,
HMOs also cease lowering premiums
because there are fewer healthy patients
to draw from non-HMO plans. This
reinforces the rise in average premiums . Thus average premiums are
higher, and HMOs have also lost their
primary means of expanding market
share. Further HMO expansion, then,
either requires new markets with little
HMO development or that HMOs
adopt new strategies of expansion.
Other factors support the conclusion that HMOs are done lowering
premiums. With less price competition from traditional insurers, HMOs
may choose to "shadow price" traditional insurers by charging premiums
just below the latter's, irrespective of
HMO costS.4 If market entry and the
acquisition of market share involves
significant overhead costs, HMOs may
attempt to recover initial investment
costs when the pressure to maintain
low premiums abates. Further, if markets are dominated by a small number
of HMOs, premiums may simply rise
with oligopoly pricing.
This overall picture is consistent with
the emergence of a "mature" market
in which a set of technical and organizational advantages is realized by
innovative firms that displace less innovative firms. Having realized the
advantages of organizational restructuring and patient sorting, HMOs now
seem to need new ways to expand.
Historically, firms in other "mature"
industries have tried to differentiate
their products to increase sales and

gain additional market share. Evidence that HMOs have begun to adopt
this strategy exists in the advertising
in which HMOs now regularly engage.
Values in Healthcare versus Values
in the Market
Healthcare may be represented as a bundle of different goods and services consumed to produce health, where
individuals demand healthcare goods
and services as inputs to a production
process whose output is their own
health. 5 This relationship is complicated by three factors: (1) health possesses many dimensions -physical,
psychological, and social-whose relationships are often not well understood;
(2) information about the ways in which
health can be produced is extensive and
complex, making consumers dependent on healthcare providers; and (3)
individuals often wish to delegate much
of their responsibility for decisionmaking to family members and healthcare
providers, because their health states can
change over the period of their interaction with healthcare providers.
One way of thinking about this is to
focus on how patients and providers
trea t healthcare decisionmaking as a
shared decisionmaking process. 6
Because individuals are often unclear
about what health states they wish to
produce, unclear about how to best
make use of healthcare, and unwilling
to be fully responsible for needed decisionmaking, they invite healthcare providers' participation in a shared
decisionmaking process. From this perspective, point (1) suggests that individuals rely on healthcare providers
to help them evaluate possible health
state outcomes, given that they typically have less understanding than providers do of the likely nature of
different health state outcomes. Point
(2) suggests that, because medical science only predicts probable outcomes,
419
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providers must be able to explain possibilities and tradeoffs between health
states associated with different medical interventions, thus "framing" individuals' evaluation of health state
outcomes. Finally, because, according
to point (3), individuals may not always
make clear choices regarding healthcare, determination of health outcomes again devolves partly on
providers who attempt to make healthcare decisions that they believe to be
in the best interest of the individual.
Emphasizing the shared character
of healthcare decisionmaking draws
our attention to an interaction between
individuals that differs from the kind
of interaction that occurs between individuals engaged in market exchange.
Suppose we think of values in the
most general sense as appraisals of
worth. In the case of market interaction, individuals' appraisals of worth
are usually taken to be their preferences. According to the usual view of
market exchange, values thus understood are "external" to individuals'
interaction in market exchange. Market participants need only know what
goods are offered or demanded and at
what prices to transact with one another. Market exchange of goods and
services makes communication regarding values unnecessary, thus isolating
individuals from one another in value
terms. Nor, according to standard economic theory, are individuals' values
altered or influenced by their market
interaction with one another. In contrast, with healthcare decisionmaking
understood as a shared process, individuals and providers jointly appraise
the worth of possible health outcomes. Their values cannot remain
"external" to their interaction, because
each must reflect on what the other
values to establish which health outcomes will be pursued.
The bundling of healthcare inputs
under shared decisionmaking, then,
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involves a role for values different from
the role they take on in the market
process. Indeed, there is a special field
of investigation specifically devoted
to this distinct realm of values and the
decisionmaking concerned. Bioethics,
or the ethics of healthcare, investigates healthcare values and how to
resolve value conflicts encountered in
making choices about how to bundle
healthcare goods and services. As an
area of applied ethics, bioethics studies the integration of the ethics of medicine and broad moral theories of wellbeing and individual righ~. More
concretely, bioethics studies how individuals and providers reach agreement regarding desirable health
outcomes. The moral theory context in
which this process is explained reflects
the fact that shared decisionmaking
over healthcare inescapably brings up
such matters as the nature of the good
life, the meaning of well-being, patient
and provider rights, personal dignity,
and so on. In economics, in contrast,
because the logic of the marketplace
explains individuals' interaction, moral
theory is left out the picture entirely,
and the only way values can be discussed is as individuals' private
preferences.
HMO Expansion and Conflict
Between Market and Nonmarket
Values
Product differentiation occurs when
firms distinguish their own goods from
those of other firms to attract consumers. Some differences are cosmetic,
whereas others alter the nature of the
good or add new features . The importance of this to HMOs seeking marketshare expansion lies in the relative
ease of each type of differentiation.
Cosmetic changes, such as in marketing, business support staff tasks, and
other matters incidental to the actual
delivery of healthcare, can usually be

Perspectives
made unilaterally by HMOs. However, changes in the nature of healthcare affecting the relationship between
individuals and providers cannot be
made without their participation. It is
this latter sort of change, however,
that is ultimately most important if
HMOs are to differentiate themselves
in terms of quality of care.
Factor into this that past changes in
HMO healthcare plans associated with
cost-containment strategies (reduced
hospital stays, less diagnostic workup, etc.) have been regarded by some
as a stripping-down process. Although
surveys show that consumers have
been largely satisfied with HMOs, they
also show concerns regarding quality
of care. The task for HMOs, then, is to
defend cost-containment strategies and
also deliver what is perceived as quality care, where quality is determined
by individual-provider shared decisionmaking. Consider the controversy over
mothers' length of hospital stay after
giving birth. Individuals and providers have been outspoken in criticizing
HMOs' short hospital stay policies as
harmful to the health of mothers and
infants. HMOs have thus had to scale
back cost guidelines or offer outpatient care seen to be of comparable
quality. Because both options add to
costs, neither has been adopted without pressure. In this instance, then,
quality-enhancing product differentiation has not only required backtracking on cost-containment strategies but
also a shift in control away from HMO
managers.
Will HMOs, then, continue to expand
by emphasizing quality of care? My
view is that they may but that this
may require introducing a significant
role for nonmarket values. On the one
hand, product differentiation could
raise HMO sales and revenue by as
much or more as it increases costs;
thus profits-the HMO measure of
health-need not fall and might even

rise. In effect, the increased extent of
the market could compensate for the
higher per-person cost of care. But on
the other hand, because this development would seem to involve an
expanded role for individual-provider
decisionmaking, it would enlarge the
place of nonmarket values in HMO
healthcare delivery. Ironically, then,
whereas other expansions of the market into social domains previously not
organized along market lines have been
labeled "imperialistic" on account of
the incursion of market values into
nonmarket value domains, in this
instance the reverse seems quite possible. The further expansion of HMOs
may rather require significant compromise in market principles. Should this
indeed be the case, the reason that
nonmarket values might have this role
would seem to come down to the atypical nature of healthcare as a commodity: its delivery and provision depends
on a shared decisionmaking process
between individual and provider-a
relationship that makes value "internal" to exchange rather than "external" as in most other kinds of markets.
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